LSI Alumni Funding Report Q3 2025

In Q3 of 2025, LSI Alumni raised over $925 million across 40+ deals, including two M&A transactions and two IPOs. Our quarterly Alumni Funding Report features transactions made by these medical device startups and their investors.

To view the full report with the deals, companies, and investors involved, sign up for a free Compass account here.

Lucida Medical

Lucida Medical was awarded a £2.25 million SBRI Healthcare contract to expand deployment of its AI-powered prostate cancer diagnostic platform across the NHS. The funding supports implementation of Lucida Medical’s Prostate Intelligence™ system in up to 15 hospitals, where it will accelerate diagnosis, reduce unnecessary biopsies, and improve access to earlier, more accurate care.

Investors/Deal Details: Small Business Research Initiative (SBRI) Healthcare

RECORNEA

RECORNEA closed an oversubscribed €1.2 million Seed round to advance minimally invasive corneal disease therapies. The funding supports RECORNEA’s first-in-human clinical trial of the GROSSOⓇ Reshaper for keratoconus and enables continued development of its minimally invasive super-elastic nitinol solutions.

Investors/Deal Details: ENEA Tech e Biomedical (led), B Heroes, Caique Holding, DN Lemans, Scientifica, and Health Wildcatters

Cooler Heads Care

Cooler Heads Care closed an $11 million oversubscribed Series A round to scale Amma™, the only FDA-cleared portable scalp cooling system. The financing will expand the manufacturing and rollout of Amma™ to help chemotherapy patients preserve their hair, privacy, and dignity during treatment.

Investors/Deal Details: Mutual Capital Partners (led), SHD Partners, Crescent Ridge VC, Cal Innovation Fund, NuFund, Robin Hood Ventures, Golden Seeds, HIP VC, and an unnamed strategic investor

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/lsi-alumni-funding-report-q3-2025

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more